NYSE:ZBH • US98956P1021
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ZIMMER BIOMET HOLDINGS INC (ZBH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-12 | Barclays | Maintains | Underweight -> Underweight |
| 2026-02-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-10 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-10 | Needham | Reiterate | Hold -> Hold |
| 2026-01-28 | UBS | Maintains | Sell -> Sell |
| 2026-01-09 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2026-01-08 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-05 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2025-12-16 | Baird | Downgrade | Outperform -> Neutral |
| 2025-12-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-11-10 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-11-06 | UBS | Maintains | Sell -> Sell |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-06 | Barclays | Maintains | Underweight -> Underweight |
| 2025-11-06 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-11-05 | BTIG | Maintains | Buy -> Buy |
| 2025-11-05 | Barclays | Maintains | Underweight -> Underweight |
| 2025-10-22 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-10-13 | BTIG | Maintains | Buy -> Buy |
| 2025-10-07 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-09-19 | Stifel | Maintains | Buy -> Buy |
| 2025-09-18 | Rothschild & Co | Initiate | Buy |
| 2025-08-08 | UBS | Maintains | Sell -> Sell |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.394B 6.55% | 7.679B 3.85% | 8.232B 7.20% | 8.637B 4.93% | 8.958B 3.72% | 9.274B 3.53% | 9.536B 2.83% | 10.279B 7.79% | 10.324B 0.44% | 10.744B 4.07% | |
| EBITDA YoY % growth | 2.425B 12.65% | 2.555B 5.38% | 2.473B -3.22% | 2.926B 18.33% | 3.025B 3.38% | 3.094B 2.28% | 3.27B 5.69% | 3.443B 5.29% | N/A | N/A | |
| EBIT YoY % growth | 1.473B 20.15% | 1.559B 5.83% | 1.379B -11.54% | 2.29B 66.07% | 2.401B 4.85% | 2.486B 3.54% | 2.691B 8.25% | 2.847B 5.80% | N/A | N/A | |
| Operating Margin | 19.92% | 20.30% | 16.75% | 26.51% | 26.80% | 26.81% | 28.22% | 27.70% | N/A | N/A | |
| EPS YoY % growth | 7.56 9.72% | 8.00 5.82% | 8.20 2.50% | 8.48 3.40% | 9.09 7.19% | 9.64 6.09% | 10.31 6.91% | 11.26 9.24% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.88 3.64% | 2.07 -0.03% | 1.97 3.69% | 2.51 3.82% | 2.01 7.22% | 2.22 7.43% | 2.24 13.76% | 2.59 3.10% |
| Revenue Q2Q % growth | 2.085B 9.21% | 2.168B 4.37% | 2.096B 4.73% | 2.354B 4.91% | 2.167B 3.93% | 2.298B 6.00% | 2.203B 5.10% | 2.441B 3.70% |
| EBITDA Q2Q % growth | 675.92M 13.52% | 716.93M -22.74% | 705.34M -38.73% | 819.77M -40.97% | 728.03M 7.71% | 794.36M 10.80% | 738.07M 4.64% | 808.95M -1.32% |
| EBIT Q2Q % growth | 526.35M 54.35% | 567.29M 41.22% | 550.95M 61.38% | 687.29M 132.98% | 568.04M 7.92% | 637.59M 12.39% | 608.14M 10.38% | 680.99M -0.92% |
All data in USD
35 analysts have analysed ZBH and the average price target is 105.6 USD. This implies a price increase of 13.31% is expected in the next year compared to the current price of 93.2.
ZIMMER BIOMET HOLDINGS INC (ZBH) will report earnings on 2026-05-04, before the market open.
The consensus EPS estimate for the next earnings of ZIMMER BIOMET HOLDINGS INC (ZBH) is 1.88 USD and the consensus revenue estimate is 2.08B USD.
The consensus rating for ZIMMER BIOMET HOLDINGS INC (ZBH) is 67.4286 / 100 . This indicates that analysts generally have a neutral outlook on the stock.